ME Earnings

ME reported its FY2024Q4 earnings on 2024-05-23, showcasing a revenue of 64.03M against an estimate of 61.45M, resulting in a 4.2% surprise. The EPS was -0.12, surpassing the expected 0 by 0%. The stock experienced a -2.68% price change on the earnings day and a 6.69% change over the next five days, reflecting market reactions to the results.

Following ME's FY2024Q4 earnings announcement on 2024-05-23, the stock price moved by -2.68% on the day of the release. Over the subsequent five days, it saw a 6.69% change. Historically, ME's stock price tends to shift by an average of 0.2% in the 10 days leading up to earnings and -20.63% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate ME's annual revenue to reach 65.00M, while the EPS is projected at -2.95. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ME's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ME's stock price typically moves by 0.2% in the 10 days before its earnings and -20.63% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -2.95 and revenue of 65.00M.

The earnings call indicates several concerns: a 12% revenue decrease, a significant cash position decline, and a going concern disclosure. Although cost-cutting measures are in place, the company is discontinuing therapeutic programs and reducing its workforce by 40%, which suggests financial strain. The Q&A section reveals a focus on restructuring and compliance, but lacks specific recovery timelines. The absence of a shareholder return plan and competitive pressures further contribute to a negative outlook, likely resulting in a stock price decrease of -2% to -8% over the next two weeks.